US Patent

US9393203 — Osmotic drug delivery system

Method of Use · Assigned to Supernus Pharmaceuticals Inc · Expires 2026-04-27 · 0y expired

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an osmotic drug delivery system for highly water-soluble drugs that exhibit an erratic or incomplete release profile.

USPTO Abstract

An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.

Drugs covered by this patent

treprostinil-diolamine (TREPROSTINIL DIOLAMINE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1877`	—	treprostinil-diolamine
`U-1877`	—	treprostinil-diolamine
`U-1877`	—	treprostinil-diolamine
`U-1877`	—	treprostinil-diolamine
`U-1877`	—	treprostinil-diolamine

Patent Metadata

Patent number: US9393203
Jurisdiction: US
Classification: Method of Use
Expires: 2026-04-27
Drug substance claim: No
Drug product claim: Yes
Assignee: Supernus Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.